Progenics Pharmaceuticals (FRA:PGP) Scaled Net Operating Assets : 0.45 (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Progenics Pharmaceuticals's operating assets for the quarter that ended in Mar. 2020 was €62.28 Mil. Progenics Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2020 was €13.46 Mil. Progenics Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2019 was €107.52 Mil. Therefore, Progenics Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2020 was 0.45.

Progenics Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Progenics Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Scaled Net Operating Assets Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.12

0.10

0.06

0.36

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.19	0.28	0.32	0.45	0.45

Competitive Comparison of Progenics Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Progenics Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Progenics Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Scaled Net Operating Assets falls into.

Progenics Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Progenics Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2019 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2019 )
=	(Operating Assets (A: Dec. 2019 )	-	Operating Liabilities (A: Dec. 2019 ))	/	Total Assets (A: Dec. 2018 )
=	(69.679	-	16.457)	/	148.988
=	0.36

where

	Operating Assets		(A: Dec. 2019 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	107.523	-	37.844
=	69.679

	Operating Liabilities		(A: Dec. 2019 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	65.625	-	42.224	-	6.944
=	16.457

Progenics Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2020 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2020 )
=	(Operating Assets (Q: Mar. 2020 )	-	Operating Liabilities (Q: Mar. 2020 ))	/	Total Assets (Q: Dec. 2019 )
=	(62.275	-	13.464)	/	107.523
=	0.45

where

	Operating Assets		(Q: Mar. 2020 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	89.001	-	26.726
=	62.275

	Operating Liabilities		(Q: Mar. 2020 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	61.297	-	40.723	-	7.11
=	13.464

Progenics Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023